ArticleJournal of molecular histology2025
RING box protein-1 promotes the metastasis of cervical cancer through regulating matrix metalloproteinases via PI3K/AKT signaling pathway.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- RBX1Cancers · 2026Article
- Genetically Predicted Gene Expression and Circulating Metabolites Associated with Cervical High-Grade Squamous Intraepithelial Lesion: A Mendelian Randomization Study.International journal of women's health · 2026Article
- The Characteristics and Expression ofInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer (CC) remains a leading cause of cancer mortality amongst females worldwide. Some of the CC patients may experience early metastases of the primary tumor, however the underlying mechanism remains unclear. Aberrant expression of RING box protein-1 (RBX1), a subunit in the E3 ubiquitin ligase family, has been reported in several cancer types. Nevertheless, little is known regarding the role of RBX1 in the metastasis of CC patients. In this study, we examined the expression of RBX1 from 90 biopsies of CC patients, and found a significantly increased expression of RBX1 in the tumor tissues compared to the normal tissues. Notably, the abundance of RBX1 in the CC patients with metastasis was higher than their counterparts without metastasis, suggesting that RBX1 may play a significant role in the modulation of CC metastasis. Furthermore, by using Hela cells as a model of CC in vitro, we demonstrated that ectopic over-expression of RBX1 could significantly promote the migration and invasion of Hela cells, whereas knockdown of RBX1 could remarkably suppress the migration and invasion of Hela cells. Mechanistically, the regulatory effect of RBX1 on cell metastasis was associated with changes in matrix metalloproteinases (MMP3 and MMP9) and altered activity of PI3K/AKT signaling. In conclusion, this study highlighted RBX1 as a novel target that can promote the metastasis of Hela cells in vitro, which may contribute to the development of alternative therapeutic options for CC patients.
Indexed as
Identifiers
40153066What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.